StockStory.org on MSN5d
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics StocksAs the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...
Myriad Genetics has a 1-year low of $9.36 and a 1-year high of $29.30. The firm has a market cap of $885.70 million, a price-to-earnings ratio of -7.46 and a beta of 1.79.
Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...
Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective dropped by investment analysts at UBS Group from $18.00 to $16.00 in a note issued to investors on Tuesday,Benzinga reports. The ...
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 7.1% year on year to $210.6 million. The company’s full-year ...
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...
Good day, and thank you for standing by. Welcome to the Myriad Genetics Fourth Quarter 2024 Financial Earnings Conference Call. At this time, all participants are in a listen-only mode.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback